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Notch signaling has been demonstrated to have a central role in glioblastoma (GBM) cancer stem
cells (CSCs) and we have demonstrated recently that Notch pathway blockade by g-secretase
inhibitor (GSI) depletes GBM CSCs and prevents tumor propagation both in vitro and in vivo. In
order to understand the proteome alterations involved in this transformation, a dose-dependent
quantitative mass spectrometry (MS)-based proteomic study has been performed based on the
global proteome profiling and a target verification phase where both Immunoassay and a multiple
reaction monitoring (MRM) assay are employed. The selection of putative protein candidates for
confirmation poses a challenge due to the large number of identifications from the discovery
phase. A multilevel filtering strategy together with literature mining is adopted to transmit the
most confident candidates along the pipeline. Our results indicate that treating GBM CSCs with
GSI induces a phenotype transformation towards non-tumorigenic cells with decreased prolif-
eration and increased differentiation, as well as elevated apoptosis. Suppressed glucose metabo-
lism and attenuated NFR2-mediated oxidative stress response are also suggested from our data,
possibly due to their crosstalk with Notch Signaling. Overall, this quantitative proteomic-based
dose-dependent work complements our current understanding of the altered signaling events
occurring upon the treatment of GSI in GBM CSCs.
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1 Introduction
Glioblastoma multiforme (GBM) is the most aggressive
class of brain tumors and 80% of patients with GBM survive
only for 1–2 years after diagnosis [1]. The emerging evidence
for the involvement of brain cancer stem cells (CSCs) in the
initiation and propagation of brain tumors, particularly
GBM, allows for the identification of more effective ther-
apeutic targets [2]. Several groups have identified brain
tumor CSCs using cell surface markers such as CD133 and
CD15 [3–5], although currently there is no universally
accepted collection of CSC markers for isolation of a pure
population of GBM stem cells [6]. GBM neurosphere
cultures are often utilized as an alternative to provide an
advanced model for investigating GBM CSCs [7].
The importance of Notch signaling in cancer has been
firmly established and it is one of the most intensively
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studied therapeutic targets in CSCs. Increasing evidence has
implicated its central role in GBM [7–10] based on its
participation in regulation of self-renewal and cell fate
determination in normal stem cells [11]. Therefore, the
investigation of the molecular mechanism upon blocking at
multiple stages of the Notch signaling cascade become
essential where inhibition via g-secretase inhibitors (GSIs)
are the most utilized [6]. We have demonstrated in our
previous study that Notch pathway blockade by GSI targets
brain tumor CSCs through decreased proliferation and
induced differentiation and apoptosis [7, 9, 12].
The conventional biomarker discovery pipeline usually
begins with a global unbiased screening stage, which is typi-
cally MS-based. A quantitative MS proteomic approach has
been demonstrated to be a powerful tool in the study of stem
cells utilizing either stable isotope labeling methods or label-
free methods [13–16]. To gain further insight into the effects
GSI exerts on Notch signaling and other potential pathways
involved in GBM CSCs, we have employed a spectral counting-
based label-free quantitative proteomic approach to perform a
large-scale screening in global discovery phase. This initial
profiling provides us comprehensive information about the
proteome alterations, which then requires verification after
candidate prioritization via a multilevel filtering strategy. Also,
the biomarker discovery pipeline usually involves a secondary
targeted quantitative stage which traditionally relies on anti-
body-based protocols such as ELISA to follow up the proteo-
mics or genomic profiling studies [17].
Currently, there has been a trend toward the develop-
ment of targeted MS as a methodology for confirmation
based on the use of multiple reaction monitoring (MRM)
[18, 19]. The concept of monitoring specific peptides from
proteins of interest as an accurate quantification strategy is
well established, because MRM offers superior sensitivity
and selectivity for the targeted analytes and the precision is
further increased by facilitating the chromatographic
retention time as another identifier. Owing to the comple-
mentarity of immunoassay and MRM, we have explored a
combination of these two assays to verify selected high-
priority protein candidates. Moreover, literature mining was
performed together with ingenuity pathway analysis (IPA)
to relate our findings to previous publications in order to
broaden our current knowledge about the underlying
molecular mechanisms regarding alterations occurring
upon GSI treatment in GBM CSCs. A putative altered
signaling network is generated to summarize our findings
reflecting those in light of previous publications and those
newly mined from our data.
2 Experiments and materials
2.1 Cell culture and treatments
GBM neurosphere cultures were maintained in Neurocult
medium (Stem Cell Technologies, Vancouver, BC, Canada,
http://www.stemcell.com) supplemented with epidermal
growth factor (10 ng/mL) and fibroblast growth factor
(10 ng/mL) as previously described [7, 20]. For treatment
studies, cells were plated and allowed to grow overnight in
Neurocult medium; Neurocult was then replaced the next
morning with medium containing g-secretase inhibitor
([11-endo]-N-(5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]
annulen-11-yl)-thiophene-2-sulfonamide, referred to as
‘‘GSI’’) [9]dissolved in dimethyl sulfoxide (DMSO) at the
concentrations of 0, 2, 10, and 50mM. We have shown
previously that GSI can block Notch signaling pathway at
Hes1 protein expression level starting at 2 mM level [7, 9].
2.2 Cell lysis and trypsin digestion
Cells were harvested on day three and washed twice with
PBS (0.01M phosphate, 0.15M NaCl, pH 7.4) to remove
culture medium. The extraction of whole cell lysates follows
the procedure as previously described [16]. Basically, cell
pellets were resuspended in PPS (3-[3-(1,1-bisalkyl-
oxyethyl)pyridin-1-yl]propane-1-sulfonate, Protein Discov-
ery, Knoxville, TN, USA) powder dissolved in 50mM
ammonia bicarbonate at a final concentration of 0.2% m/v
together with 1% protease inhibitor cocktail. Protein
concentration was determined by Micro BCA
TM
Protein
Assay Kit (Pierce/Thermo Scientific, Rockford, USA).
Trypsin digestion, cleavage of PPS, and purification of
peptides were performed sequentially and also follow the
same protocol [16]. To be noted, PPS is unique among
special surfactants for protein solubilization in that it
produces no oily film or cloudy pellet in the protein
sample solution which may cause protein losses. The
degradation of the reagent through acid-cleavage circum-
vents the major limitation of conventional protein solubili-
zation protocols where detergent suppresses the ionization
of low-abundance species. Peptides were then lyophilized to
powder and stored in a 801C freezer for future use. All
chemicals were purchased from Sigma unless mentioned
otherwise.
2.3 Reversed-phase liquid chromatography and ESI-
ion trap mass spectrometry
Peptides were reconstituted in a solution of 5% ACN with
0.1% formic acid at a final concentration of 100 ng/mL.
Reversed-phase LC was performed by a Paradigm MG4
micropump system (Michrom Biosciences, Auburn, CA,
USA) connected to an LTQ mass spectrometer (Thermo
Finnigan, San Jose, CA, USA). Total tryptic
digests of each sample (control and three treatments) were
directly introduced into an RPLC nano-column
(3 mm 100 A˚, 0.075mm 150mm, C18 AQ particles,
Michrom) after a desalting nano-trap (300 50mm)
(Michrom). A 3 h linear gradient with 150min from 5 to
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40% ACN, 15min from 5 to 80% ACN and another 15min
for equilibrium to 5% ACN was used. The other LTQ
parameters are the same as previously described
[16]. The separated peptides were then introduced into an
LTQ equipped with a nano-spray ion source (Thermo
Electron). The LTQ was operated in data-dependent
mode in which one cycle of experiments consisting
of one full MS scan was followed by five pairs of
zoom scans and MS/MS scans with dynamic exclusion set
to 30 s. The capillary temperature was set at 1751C, spray
voltage was 2.8 kV, capillary voltage was 30V and the
normalized collision energy was 35% for fragmentation.
Each sample was analyzed in triplicate with each injection of
1mg material.
2.4 Database searching and multilevel filtering
MS/MS spectra were searched against Uniprot database
(updated 05/2010) by SEQUEST search engine incorporated
in Proteome Discoverer (version 1.1.0.263). Searching
parameters were specified as follows: (i) Fixed modification:
carbamidomethylation of Cys residue with a mass shift of
58.1Da; (ii) variable modification: oxidation of Met residue
with a mass shift of 15.99Da; (iii) two missed cleavage sites
were allowed; (iv) peptide ion mass tolerance: 1.4Da;
(v) fragment ion mass tolerance: 1.0Da; (vi) peptide charges
11, 12, and 13. Searching results were further uploaded to
Scaffold (v2.0) as msf format (the default output format
from Proteome Discoverer) and global normalization of the
spectral counts was performed subsequently. Then, a
multilevel filtering strategy consisting of four checkpoints is
adopted to capture the most confident identifications and
differentially expressed proteins. Checkpoint-1 is based on
the FDR test from target-decoy database search with a
cutoff p-value o0.05; Checkpoint-2 is according to the
Trans-Proteomic Pipeline (TPP) [21] built in Scaffold.
The criteria include protein and peptide probabilities above
95% and a minimum of two unique peptides identified for
each protein; Checkpoint-3 is tested by first generating three
lists of differentially expressed proteins by applying
Student’s t-test for 0 versus 2 mM, 0 versus 10 mM and 0
versus 50 mM with a threshold p-value o0.05 and then
retaining proteins that are present in all three lists; Check-
point-4 is a further filtering based on the literature mining
to retain proteins that have been previously reported to play
important roles in furthering CSC properties and/or
tumorigenesis.
2.5 Western blot
Western blot was performed essentially as previously
described [1]. Briefly, 20mg of total proteins from each
sample were separated by 4–20% SDS-PAGE and then
transferred to PVDF membranes (Bio-Rad, CA, USA). After
being blocked for 2 h, the membranes were incubated with
antibodies including polyclonal anti-APC5, polyclonal anti-
GFAP, monoclonal anti-ENGO, monoclonal anti-PCNA,
polyclonal anti-SODC and monoclonal anti-Actin (Abcam,
Cambridge, CA, USA) overnight. After washing three times,
the membranes were incubated with peroxidase conjugated
goat anti-rabbit or anti-mouse IgG (H1L) for 1 h. The blots
were visualized with DAB stain (Vector Laboratory, WI,
USA).
2.6 MRM assays
For the proteins of interest, the selection criteria of proteo-
lytic signature peptides include: (i) being identified from the
LTQ analysis with high confidence; (ii) a unique signature
of the target protein; (iii) a length of 8–20 amino acids;
(iv) no missed cleavage sites; (v) no post translational
modifications. Isotope-labeled standard peptides (purity 4
98%) were synthesized by Anaspec (Fremont, CA, USA),
where the C-terminal lysine or arginine was fully labeled
with 13C and 15N. The MRM assay was performed with an
Agilent 6410 triple quadrupole MS system equipped with an
Agilent 1200 LC (Agilent Technologies, New Castle, DE,
USA) in positive-ion mode. Synthetic peptides were first
reconstituted in 50% methanol. Flow injection analysis
(FIA) was used to optimize the fragmentor voltage and
collision energy determined by the intensity of precursor
ions and product ions, respectively. Up to four transitions
from each peptide were chosen to obtain the best
signal-to-noise ratio in MRM mode. A C-18 column from
Agilent with 1.8 mm particle size and 4.6 50mm dimen-
sion was used for the HPLC separation. The mobile phase is
0.1% formic acid (Solvent A) and 0.1% formic acid in ACN
(Solvent B). The linear gradient was 2–20% ACN for 1.5min
and 20–95% ACN for 5min with a flow rate of 0.6mL/min.
The desolvation gas temperature is 3501C and the capillary
voltage is 4000V. The nebulizer pressure is 45 psi and the
desolvation gas flow rate is 11 L/min.
For the monitoring of sample response, three dose (0, 2,
and 10 mM) points were interrogated with a total sample
protein injection of 10mg analyzed in duplicates. Data
analysis was carried out by Agilent Mass Hunter Quantita-
tive Analysis Software.
2.7 IPA
The three lists of differentially expressed proteins
generated after checkpoint-3 were uploaded to IPA
together with their fold changes as three different observa-
tions. Pathway analysis was then performed to infer the
significantly altered pathways associated with GSI treat-
ments. The significance values for analysis of pathway
generation were calculated using the right-tailed Fisher’s
exact t test.
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3 Results and discussion
3.1 Protein identifications and differential
expression
A 1-D separation strategy was adopted in place of a 2-D
approach used in our previous studies [16, 22] by reducing
the particle size of the nano-RPLC column from 5 to 3mm
and prolonging the gradient time from 1h to 3 h to avoid
protein losses while also saving instrument time. A total of
1127, 929, 854, and 638 proteins were identified for each
sample respectively after filtering by a threshold of
FDRo0.05. Detailed information regarding the identifica-
tions for each run can be found in Supporting Information
1. Four Venn diagrams showing the overlap of protein
identifications between samples of the same condition were
also generated to evaluate sampling reproducibility
(Supporting Information 2). For example, the three repli-
cated runs for GSI-0 mM have identified 681,720, and 725
proteins with 394 shared by all three runs. In order to
improve the confidence of protein identifications, a multi-
level filtering strategy is employed as shown in
Fig. 1. A total of 1707 proteins combining all replicate runs
across different samples were identified after checkpoint-1
and a fraction of 672 proteins were retained after
checkpoint-2. Next, three lists of differentially expressed
proteins were generated for each pair (0 versus 2 mM, 0
versus 10mM, and 0 versus 50mM) by a cut-off p-value
o0.05, resulting in 117, 187, and 213 differentially expres-
sed proteins respectively.
In previous studies, we have already shown that the
Notch signaling pathway can be blocked by treating CSCs
with 2 mM GSI [7, 9, 12]. The results indicate that the
changes of related pathways have occurred at the 2mM GSI
level; however, this was suggested by monitoring the change
in one important protein Hes 1 in the Notch pathway. In
this study, we investigated the overall protein profiling of
GBM stem cells to reveal global proteome changes upon
GSI treatment starting at the mM GSI level. Therefore,
Students’s t-test was applied to choose differentially
expressed proteins between GSI-0 mM and -2 mM. Then, we
further analyzed the protein changes of GBM stem cells
upon treatment of GSI with higher doses (10 and 50mM).
The aim was to discover if the protein changes in Notch
signaling and other potential pathways can be intensified by
increasing the doses of GSI. Therefore, only proteins exhi-
biting the same trend of changes under all three concen-
trations were considered as our candidates. Checkpoint-3
which requires the presence in all three differential
expression lists with consistent changing pattern further
narrows down the number of putative candidates to 36
(Supporting Information 4).
3.2 Evaluation of label-free quantification
Reproducibility is an essential factor to evaluate the accuracy
of a label-free-based quantification approach. It is inter-
rogated from three aspects in this study: variation of the
number of protein identifications across three technical
Figure 1. Overall
workflow.
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replicates; the correlation of spectral counts between any two
technical replicates within the same sample and the average
variation of all protein identifications based on their spectral
counts in between the technical replicates. First, the number
of total identifications passing checkpoint-1 in each replicate
run is similar to each other with a coefficient of variance
(CV) of 3, 1, 3, and 8% for each of the control and 2, 10,
50mM treatment samples, respectively. Second, high Pear-
son correlation coefficients are found by comparing any two
replicates within the same sample. For example, the coeffi-
cient is calculated to be 0.977 between [0.973, 0.982] at 95%
confidence level based on the spectral counts assigned to
each identified protein between the first and the second
technical replicate runs of the control sample. A detailed
correlation matrix between all 12 observations across
different samples can be found in Supporting Information
3. This correlation matrix was also used to generate the
clustering graph shown in Fig. 2. The four different biolo-
gical entities are clearly separated with their technical
replicates grouped under the same branch. Also, the three
treatment groups are more closely associated compared with
the control group where 2 and 10mM dose treatments tend
to be more closely related compared with the 50 mM treat-
ment. Another way to evaluate the reproducibility is by
calculating the average CV (indicated in Supporting Infor-
mation 2) for all protein identifications across technical
replicates. We have observed a consistent 30% average
variation for all four conditions.
3.3 Selection of putative protein candidates
The list of 36 protein candidates were further screened
through literature mining to link their biological roles
pertaining to CSCs properties and/or dysregulated events in
tumors. A total of 15 high-priority putative candidates were
selected as listed in Table 1 and are categorized by different
functions: proliferation, differentiation, apoptosis, tumor
invasion, oxidative response, and glycolysis. Four proteins
(proliferating cell nuclear antigen (PCNA), nestin (NEST),
drebrin (DREB), superoxide dismutase [Cu-Zn] (SODC))
from different functional categories in this table were
selected for validations by either Western blot or MRM
assays. Three proteins out of this table were also selected
because of their association with these investigated func-
tions: g-Enolase (ENOG) (alternatively: neuron-specific
enolase (NSE)) for ‘‘Proliferation’’; glial fibrillary acidic
protein (GFAP) for Differentiation; Anaphase-promoting
complex5 (APC5) for apoptosis.
3.4 Validation through Western blot
The fold changes of five proteins were validated by Western
blot experiments for two dose treatments (2 and 10mM) of
an independent control sample. Figure 3 illustrates a
consistent dose-dependent pattern detected between the
spectral counting method and Western blot experiments.
PCNA is commonly used as a cell proliferation index and a
good candidate for prognosis of tumor and cancer develop-
ment [23]. The decreased expression pattern of PCNA
detected in GBM CSCs in our study agrees with a previous
report that disruption of Notch signaling by GSI in tracheal
epithelial cells reduces PCNA expression [24] and our
previous study showing Notch pathway inhibition by GSI
reduces CSC proliferation [7, 9]. ENOG has been used as a
neuron stem cell marker [25]. A previous study of different
subgroups of GBM tumor-initiating cells shows 70% of
ENOG-positive cells have developed tumors using a mice
xenograft model [26] and the expression of ENOG are only
detected in high-grade GBMs [27]. Our finding of down-
regulated expression of ENOG may imply that GBM CSCs
exhibit a reduced tumor grade as the drug dose increases.
GFAP was chosen to verify the impact of GSI on the
differentiation of GBM CSCs. It has been previously detec-
ted in 78% differentiated brain tumor CSCs and exhibits
lack of immunoreactivity in undifferentiated CSCs [28]. Our
result of up-regulated GFAP expression indicates the treat-
ment of GSI drives GBM CSCs towards a more differ-
entiated state. There is a minor discrepancy between
spectral counting and Western blot results when comparing
the dose of 2–10 mM. Western results shows the expression
of GFAP follows a linear trend as the dose increases while
the spectral counting results do not suggest the same. This
may be due to the low base expression level of GFAP
(spectral countso10) where the error bar between technical
replicates is comparable to the variation between different
conditions. For the verification of altered apoptotic activity
upon GSI treatment, APC5 which is a subunit of the
multiprotein complex that controls mitotic progression [29]
was tested here. It is hypothesized that the abnormal regu-
lation of APC may be involved in malignant transformation
Figure 2. Cluster analysis based on the correlation matrix.
Pearson correlation coefficients are shown between technical
replicates within the same group.
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through chromosome instability [30] and the inhibition may
lead to cell death [31]. Thus, our observation of reduced
expression level of APC5 may be an indication of cell cycle
failure in GBM CSCs after treatment with GSI which in
turn promotes cell death. SODC is an important anti-
oxidant enzyme which protects cells from free radical attack
and it has been demonstrated to play a critical role in
Reactive Oxygen Species (ROS) defense and is associated
with chemoresistance and malignancy grade in astrocytic
brain tumors [32]. Thus, the reduced expression level of
SODC detected in our experiments may imply that the GSI
treatment may render GBM CSCs more vulnerable to
apoptosis by attenuating their cell defense system. Overall,
the Western blot results of these five proteins suggest three
areas of impact on GBM CSCs upon GSI treatment: reduced
proliferative potential, increased differentiation, and
enhanced apoptotic activity. All of these could be viewed as a
decrease of stem cell properties, leading to a phenotype
change.
3.5 Validation through MRM
In addition to immunoassay, MRM is also employed as
another orthogonal verification strategy to validate the
turnover of an important candidate NESTINs in this study.
NESTIN has been identified as a neural stem cell marker
and a GBM CSC marker [9, 28, 33]. We and others have
demonstrated previously that NESTIN expression is
enhanced by Notch signaling in medulloblastoma [9] and
GBM [34] and is inhibited by GSI in a dose-dependent
manner [7] in GBM CSCs. These findings were obtained by
immunostaining-related approaches. Herein, an MS-based
method was used to confirm the impact of the drug on
NESTIN expression in GBM CSCs.
Two peptides from NESTIN were chosen according to the
peptide selection criteria described in the experimental
section. Table 2 shows the parent and fragment ion masses
for the target peptides and heavy standard peptides. The
most intense ions were selected for monitoring. Supporting
Information 5 shows the MS/MS spectra used for the
selection of the transitions. A total of four transitions were
monitored for light and heavy GPPAPAPEVEELAR, and two
transitions for light and heavy SLETEILESLK. Supporting
Information 6 shows representative transitions for these
Table 1. List of high-priority protein candidates after multilevel filtering
Functions Accession Protein name Gene name p-Value
Proliferation PCNA_HUMAN Proliferating cell nuclear antigen PCNA 0.0016k
NEST_HUMAN Nestin NES 0.0067k
PA2G4_HUMAN Proliferation-associated protein 2G4 PA2G4 0.0080k
Differentiation TBB3_HUMAN Tubulin b-3 chain TUBB3 0.0241m
Apoptosis 1433B_HUMAN 14-3-3 Protein b/a YWHAB 0.0028k
VDAC1_HUMAN Voltage-dependent anion-selective channel protein 1 VDAC1 0.0030k
1433T_HUMAN 14-3-3 protein theta YWHAQ 0.0053k
1433F_HUMAN 14-3-3 protein eta YWHAH 0.0116k
PDIA1_HUMAN Protein disulfide-isomerase P4HB 0.0093k
TCPB_HUMAN T-complex protein 1 subunit b CCT2 0.0128k
1433E_HUMAN 14-3-3 protein epsilon YWHAE 0.0139k
Tumor Invasion DREB_HUMAN Drebrin DBN1 0.0043k
MYH9_HUMAN Myosin-9 MYH9 0.0191k
Oxidative Response SODC_HUMAN Superoxide dismutase [Cu-Zn] SOD1 0.0238k
Glycolysis KPYM_HUMAN Pyruvate kinase isozymes M1/M2 PKM2 0.0186k
p-Value shown here is the average from the three pairs student t-tests. k indicates down-regulation of a protein after GSI treatment;
m indicates up-regulation of a protein after GSI treatment.
Figure 3. The upper panel shows the spectral counts detected for
each protein across replicate runs within each sample. The lower
panel shows the corresponding Western blot results. The
direction of arrow indicates either up or down-regulated
expression.
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peptides in 0, 2, and 10mM GSI-treated samples, while
Supporting Information 7 shows all of the measured tran-
sitions for light and heavy SLETEILESLK. As expected, all
transitions from each targeted peptide and its corresponding
heavy standard were eluted at the same time.
The dose-dependent results from label-free data and the
MRM data are shown in Fig. 4. Basically, the differential
expression of NESTIN from the MRM results was consistent
with the label-free quantitation data. As demonstrated by
both of these methods, NESTIN exhibited reduced expres-
sion level along with increased GSI dosage. The expression
level of NESTIN was reduced by 1.3–3.5-fold when treat-
ing GBM CSCs with 2 and 10 mM GSI. This is in line with
our previous report that a reduced mRNA NESTIN expres-
sion is detected from 1.5 to 4-fold after treating GBM
CSCs with GSI at 2 and 10mM [7].
3.6 Altered signaling events upon GSI treatment
Based on the knowledge obtained from a combination of
literature mining and data mining, candidate proteins listed
in Table 1 and three proteins out of this table that have been
verified (APC5, GFAP, and ENOG) were integrated to
construct a putative altered signaling network after treating
GBM CSCs with GSI, as depicted in Fig. 5. In addition,
another three proteins were also imported: Thioredoxin
(THIO/Trx), T-complex protein 1 subunit eta (TCPH/CCT7)
and Hexokinase-1(HKX1). The first two proteins success-
fully passed checkpoint-2 with a p-value o0.05 in 0 versus
10mM and 0 versus 50 mM treatments although they are not
differentially expressed after 2 mM treatment. The third
protein passed checkpoint-1 but did not pass checkpoint-2
and it shows decreased expression upon 10 and 50 mM
treatment. The correlation between these proteins and their
targeted functions are listed in Table 3.
The majority of altered signaling events depicted in this
figure are mediated through the Notch signaling cascade.
Upon blockade of the Notch pathway, proliferation of CSCs
is selectively reduced [7], which is supported by our finding
of decreased expression level of four key proteins: NESTIN,
ENOG, PCNA, and proliferation-associated protein 2G4
(PA2G4). Also, differentiation is induced [7] which can be
indicated by the elevated expression levels of two marker
proteins for differentiated neural cells: GFAP and tubulin
b-3 chain (TBB3). Previous studies in multiple myeloma
report that activation of Notch signaling inhibits apoptosis
while inhibition of Notch induces apoptosis [35, 36]. We also
have demonstrated that Notch inhibition by GSI induces
apoptosis in medulloblastoma and GBM [7, 9, 12]. Our
results are in line with this where the blockade of Notch
Table 2. Summary of the target peptides information and the transitions used for MRM analysis of Nestin
Peptide Sequence Label type Charge Parent ion Product ion
Pep-1 SLETEILESLK Unlabeled 21 631.4 173
201
SLETEILESLK Isotope-labeled 21 635.1 173
201
Pep-2 GPPAPAPEVEELAR Unlabeled 21 716.9 127
155
252
323
GPPAPAPEVEELAR Isotope-labeled 21 721.7 127
155
252
323
K5 Lys(13C6
15N2); R
5Arg(13C6
15N4).
Figure 4. Summary of the comparison between the fold change
results obtained from label-free quantification by LTQ and MRM
quantification by QqQ. The y-axis in the upper bar chart repre-
sents a ratio of fold changes by dividing the response from each
treatment by control. The response of control is normalized to
‘‘1’’. The lower panel provides the mean and CV of the spectral
counts information for Nestin in each sample. ‘‘Spectral Counts’’
is abbreviated as ‘‘Sp’’.
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activates apoptosis in GBM CSCs. This is supported by the
detection of a reduced expression level of APC5, protein
disulfide-isomerase (PDIA1), voltage-dependent anion-
selective channel protein 1 (VDAC1), TCPB and 1433
proteins, all of which have been reported to be negatively
correlated with apoptosis [31, 37–44]. In addition, decreased
tumor invasion capability is inferred and supported by the
detection of reduced expression of DREB and myosin-9
(MYH9) which are identified to be positively correlated with
metastasis [45–47].
Another signaling cascade we speculate to be down-
regulated is NFR2-mediated oxidative response which
contributes to cellular protection against oxidative insults
and chemical carcinogens [48]. The decreased expression
levels of its downstream transcriptional gene products, such
as anti-oxidant proteins, SODC and THIO, and a molecular
chaperone protein, TCPH, imply that this cellular defense
system against ROS has been attenuated [32, 49–51]. As
aforementioned, treating GBM CSCs with GSI tends to
abrogate the stem cell properties [7]. It is thus reasonable to
infer that the decreased oxidative defense capability is also
correlated with a phenotype transformation from CSCs
towards non-tumorigenic cells. This hypothesis is in light of
the recent significant discoveries that subsets of CSCs in
some tumors contain an enhanced defense system
compared to non-tumorigenic progeny suggested by lower
ROS levels [52–53]. However, it is uncertain at this point
that the down-regulation of NFR2-mediated oxidative
response is attributed to the direct impact from the impaired
g-secretase activity or via its newly proposed crosstalk
mechanism with Notch signaling [54].
In addition, the glucose metabolism pathway glycolysis is
also suggested to be down-regulated. Most cancer cells rely
on anaerobic metabolism even with an abundance of oxygen
rather than mitochondrial oxidative phosphorylation for
normal differentiated cells and the glycolytic rate is
increased to compensate for the less efficient production of
ATP, a phenomenon referred to as the ‘‘Warburg effect’’
[55]. The expression of two out of three rate-limiting key
enzymes in glycolysis: pyruvate kinase isozymes M1/M2
(KPYM) and HKX1, were found to be decreased from our
label free quantitative data, which may imply a decrease of
Figure 5. Putative altered signaling events occurring upon treatment of GSI. From our current understanding: GBM CSCs signals Notch
pathway leading to a constitutive activation. Sequentially, Notch signaling activates the proliferation and maintenance of the undiffer-
entiated CSCs, while suppressing apoptosis and differentiation. Treating GBM CSCs with GSI impairs Notch signaling and therefore
reverses the above effects, which is suggested from our results and previous publications. In addition, NFR2-mediated oxidative response
and glycolysis are also suggested to be down-regulated from our results possibly due to their crosstalk with Notch signaling. Solid line/
arrow indicates a conclusion that is drawn based on our results and/or from previous publications with higher confidence. Dashed line/
arrow indicates our hypothesis. The direction of an arrow placed in each node represents up/down-regulation of this protein or signaling
pathway, while the arrow used to link adjacent nodes represents activation and the blunt end represents inhibition. Blue arrow/line
indicates the native state of GBM CSCs while yellow arrow/line indicates the alterations occurring upon GSI treatment. Black arrow
indicates the up/down-regulation detected in this study while red arrow indicates the ones that have been further validated by orthogonal
approaches in our experiment.
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glycolytic rate after blockade of Notch signaling. This
inference regarding the relationship between Notch pathway
and glycolysis could be supported by previous investigations
showing that Notch signals promote glucose metabolism
mediated by the PI3K/AKT pathway [56] and our previous
finding showing that Notch pathway blockade by GSI
reduces AKT phoshorylation in medulloblastoma and GBM
[7, 9, 12]. Another study of Pre-T cells has also shown that
the withdrawal of Notch signaling reduced AKT phosphor-
ylation and decreased the glycolytic rate [57]. Moreover, the
PI3K/AKT pathway has been shown to stimulate aerobic
glycolysis in cancer cells [58] and directly enhance glucose
capture by HKX1 [59]. Therefore, we hypothesize that the
blockade of Notch Pathway upon GSI treatment decreases
PI3K/AKT signaling which further suppresses glycolysis.
Another explanation to the hypothetical decreased glucose
metabolism is that GSI treatment may induce a mechanistic
switch back to aerobic metabolism so that the accelerated
production of pyruvate is not needed; hence the glucose
metabolism is down-regulated. There is no available
evidence indicating that the impaired g-secretase activity has
a direct impact on the suppression of glycolysis.
Another interesting link between NFR2 oxidative
response and glycolysis is the level of ROS. The generation
of ROS has been postulated to be increased as the glycolytic
rate is reduced [59] and also as the oxidative defense
decreased in non-tumorigenic cells compared to CSCs [53].
We have discussed above our inferences that the treatment
of GSI drives a transformation towards non-tumorigenic
cells, suppresses the cell defense capability and down-
regulates aerobic glycolysis. Thus, it is also reasonable to
infer that the level of ROS is increased after the treatment in
GBM CSCs, although it is uncertain about the alteration
mechanism of mitochondrial oxidative phosphorylation
which is the major cellular source of ROS production.
3.7 IPA
To gain additional insight from our data, an alternative data
mining tool was utilized to construct significantly affected
canonical pathways upon GSI treatment by IPA. Glycolysis,
NFR2-mediated oxidative stress response and PI3K/AKT
signaling are captured as the most significant canonical
pathways which provide another piece of evidence to
support our hypothesis from a bioinformatics perspective.
Other important signaling pathways are also shown
including VEGF signaling, cell cycle, and hypoxia signaling,
etc. This may be attributed to the demonstrated crosstalk
between Notch signaling and these pathways [60, 61] or GSI
may also have direct impact on these pathways. The detailed
pathway lists can be found in Supporting Information 8.
One needs to be careful about the interpretation of the level
of the significance between the treatments. The length of
the bar indicates a level of association that is by no means
indicative of either up or down regulation. Also, most of the
pathways appear to be increasingly significant in the third
treatment (50 mM GSI). This may be because more proteins
are differentially expressed between the treatment and the
control as the dosage increases. Thus, the increased number
of imported proteins may affect the outcome of the statistic
algorithm (Fisher’s exact t-test) adopted by IPA for the
calculation of significance by inducing a smaller p-value.
4 Concluding remarks
In summary, this work adopts a label-free quantitative
global proteomic approach together with Immunoassay and
MRM assays to conduct a dose-dependent investigation on
the proteome alterations upon the treatment of GSI in GBM
CSCs. It demonstrates a work-flow from global discovery,
candidate prioritization to verification phase which could be
applied to other studies as well. By coupling our results with
previous literature reports from our group and others, a
putative signaling network consisting of 21 candidate
proteins with 7 being verified is generated to reflect our
inference of the underlying molecular alterations upon GSI
treatment. The downstream effects resulting from the
blockade of Notch signaling are suggested to include a
reduced proliferative potential, an increased differentiation
and an elevated apoptotic activity, leading to a phenotype
transformation towards non-tumorigenic cells. Novel
involvement of the down-regulated NFR2-mediated
oxidative stress response and glycolysis are implied as a
consequence of GSI treatment, possibly due to their cross-
talk to Notch signaling. These findings regarding the
Table 3. Correlation between the proteins used for constructing
the altered signaling network and their targeted
functions
Functions Protein Correlation Reference
Proliferation PCNA 1 [23, 24]
NEST 1 [7, 9, 27, 32, 33]
PA2G4 1 [13]
ENOG 1 [25, 26]
Differentiation TBB3 1 [27]
GFAP 1 [27]
Apoptosis APC5 – [30]
PDIA1 – [39, 40]
VDAC1 – [41, 42]
TCPB – [43]
1433-serise – [44]– [46]
Tumor invasion DREB 1 [36]
MYH9 1 [47, 48]
Oxidative
response
SODC 1 [31]
THIO 1 [50, 51]
TCPH 1 [52]
Glycolysis KPYM 1 [59]
HKX1 1 [59]
‘‘1’’ indicates positive association and ‘‘–’’ indicates negative
association, which are learned from the previous literature
publications as listed in the ‘‘Reference’’ column.
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alterations occurring on the proteome level and the signal-
ing/metabolic pathway level provide enriched information
that could broaden our current knowledge about drug
mechanism, contributing to the identification of novel drug
targets to develop better therapies for treating this dismal
disease.
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